4.54
price up icon6.82%   0.29
after-market Handel nachbörslich: 4.45 -0.09 -1.98%
loading
Schlusskurs vom Vortag:
$4.25
Offen:
$4.31
24-Stunden-Volumen:
1.61M
Relative Volume:
1.07
Marktkapitalisierung:
$248.82M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-1.4934
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+41.43%
1M Leistung:
+34.72%
6M Leistung:
-10.10%
1J Leistung:
-41.19%
1-Tages-Spanne:
Value
$4.28
$4.69
1-Wochen-Bereich:
Value
$3.065
$4.69
52-Wochen-Spanne:
Value
$2.41
$10.37

Solid Biosciences Inc Stock (SLDB) Company Profile

Name
Firmenname
Solid Biosciences Inc
Name
Telefon
617-337-4680
Name
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Name
Mitarbeiter
100
Name
Twitter
@SolidBioDMD
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
SLDB's Discussions on Twitter

Vergleichen Sie SLDB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLDB
Solid Biosciences Inc
4.54 248.82M 14.79M -102.44M -91.73M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-08 Eingeleitet Truist Buy
2024-12-13 Eingeleitet Wedbush Outperform
2024-12-10 Eingeleitet JMP Securities Mkt Outperform
2024-07-15 Hochstufung JP Morgan Neutral → Overweight
2024-06-24 Hochstufung Leerink Partners Market Perform → Outperform
2024-05-31 Fortgesetzt Piper Sandler Overweight
2024-03-28 Eingeleitet William Blair Outperform
2024-03-15 Eingeleitet Citigroup Buy
2024-03-14 Hochstufung Piper Sandler Neutral → Overweight
2023-12-08 Eingeleitet H.C. Wainwright Buy
2021-07-12 Eingeleitet Piper Sandler Neutral
2021-05-27 Eingeleitet Jefferies Buy
2021-03-16 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-03-09 Eingeleitet Barclays Overweight
2021-01-08 Hochstufung Credit Suisse Underperform → Neutral
2020-07-28 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-05-07 Herabstufung Evercore ISI Outperform → In-line
2019-10-11 Eingeleitet Evercore ISI Outperform
2019-08-29 Herabstufung Citigroup Neutral → Sell
2019-08-19 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-08-16 Hochstufung Chardan Capital Markets Neutral → Buy
2019-05-14 Herabstufung Credit Suisse Neutral → Underperform
2019-05-14 Herabstufung Goldman Neutral → Sell
2019-02-08 Hochstufung Citigroup Sell → Neutral
2019-02-08 Herabstufung SVB Leerink Outperform → Mkt Perform
2018-11-06 Eingeleitet Citigroup Sell
2018-09-06 Eingeleitet Credit Suisse Neutral
Alle ansehen

Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten

pulisher
Jun 06, 2025

Solid Biosciences (SLDB) Maintains Market Outperform Rating | SLDB Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Transcript : Solid Biosciences Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com

Jun 06, 2025
pulisher
Jun 05, 2025

Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.

Jun 05, 2025
pulisher
Jun 03, 2025

Solid Biosciences (SLDB) Announces Stock Grants Under Inducement Plan | SLDB Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 03, 2025
pulisher
Jun 03, 2025

Solid Biosciences Awards Strategic RSU Grants: New Hires Receive 34,550 Shares Under Nasdaq Compensation Rule - Stock Titan

Jun 03, 2025
pulisher
Jun 01, 2025

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Northern Trust Corp Has $676,000 Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 31, 2025
pulisher
May 30, 2025

Solid Biosciences Reports Increased Loss Amid R&D Expansion - TipRanks

May 30, 2025
pulisher
May 30, 2025

BNP Paribas Financial Markets Acquires New Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 30, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Buys Shares of 51,972 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 29, 2025
pulisher
May 28, 2025

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Solid Biosciences Leadership Team to Reveal Latest Genetic Medicine Strategy at Major Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 27, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

May 27, 2025
pulisher
May 26, 2025

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Research Analysts Set Expectations for SLDB FY2025 Earnings - Defense World

May 26, 2025
pulisher
May 22, 2025

Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fi - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fitzgerald | SLDB Stock News - GuruFocus

May 22, 2025
pulisher
May 20, 2025

Solid Biosciences (NASDAQ:SLDB) Given New $15.00 Price Target at Chardan Capital - Defense World

May 20, 2025
pulisher
May 19, 2025

Solid Biosciences (SLDB) Maintains Buy Rating Amid Revised Price Target | SLDB Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Chardan Adjusts Price Target on Solid Biosciences to $15 From $16, Maintains Buy Rating - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Q1 Earnings Forecast for SLDB Issued By William Blair - Defense World

May 19, 2025
pulisher
May 18, 2025

Wedbush Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World

May 18, 2025
pulisher
May 17, 2025

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences (SLDB) Target Price Updated by Wedbush Analyst - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks

May 16, 2025
pulisher
May 16, 2025

Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks

May 15, 2025
pulisher
May 15, 2025

SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Form 424B5 Solid Biosciences Inc. - StreetInsider

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates | SLDB Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Provides Business Update and Financial Results for Q1 2025, Advances Gene Therapy Programs for Duchenne Muscular Dystrophy, Friedreich's Ataxia, and CPVT - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

Solid Biosciences Reports Breakthrough in Duchenne Treatment: Q1 Results Reveal Strong Pipeline Progress - Stock Titan

May 15, 2025
pulisher
May 14, 2025

Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Partner With Us - Solid Biosciences

May 13, 2025
pulisher
May 10, 2025

Solid Biosciences Reports Quarterly Loss Per Share Of $0.54 - Reuters

May 10, 2025
pulisher
May 09, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: Axsome Therapeutics (AXSM), Premier (PINC) and Solid Biosciences (SLDB) - The Globe and Mail

May 09, 2025
pulisher
May 07, 2025

Solve FSHD supports Armatus Bio drug for facioscapulohumeral muscular dystrophy - BioWorld MedTech

May 07, 2025
pulisher
May 06, 2025

Invesco Ltd. Invests $49,000 in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World

May 06, 2025

Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):